Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period
NCT04957693 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2023-04-21
Summary
The aim of the present trial is to evaluate the effect of lifestyle changes on the natural history of indolent lymphomas, during the period of watchful waiting. The intervention program is comprised of specifically designed vegan nutrition, physical activity, mostly aerobic, and stress reduction by relaxation and meditation. Outcome results will be followed and analyzed for 3 years, taking into consideration the following parameters - disease burden, specific disease-related symptoms, relevant blood tests, body weight, indicators of well-being. Changes in these parameters will be correlated with the level of compliance and adherence to the intervention program. The results of the trial group of patients will be further compared to the natural history of the disease in a comparable group of patients during their waiting period who were not subject to the above intervention.
Conditions
- Indolent Lymphoma
Interventions
- BEHAVIORAL
-
vegan diet and lifestyle changes
vegan diet and lifestyle changes
Sponsors & Collaborators
-
KaMaH - The Center for Health-Promoting Therapies
collaborator UNKNOWN -
Tel-Aviv Sourasky Medical Center
lead OTHER_GOV
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-05
- Primary Completion
- 2025-07-01
- Completion
- 2025-10-01
Countries
- Israel
Study Locations
More Related Trials
-
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
NCT03078855 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
NCT00039195 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant
NCT02109809 ·Status: TERMINATED ·Phase: NA
-
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1
-
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
NCT02964858 ·Status: RECRUITING ·Phase: NA
-
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
NCT00695786 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
NCT00322985 ·Status: COMPLETED ·Phase: PHASE2
-
Low Grade Lymphoma
NCT01698866 ·Status: UNKNOWN ·Phase: PHASE4
-
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
NCT00765245 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
NCT00880581 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
NCT01359592 ·Status: COMPLETED ·Phase: PHASE2
-
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Trial of Intermediate Radiation Dose For Lymphoma
NCT05284825 ·Status: UNKNOWN ·Phase: NA
-
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
NCT00689845 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Aggressive Localized Lymphoma
NCT00841945 ·Status: TERMINATED ·Phase: PHASE3
-
the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy
NCT04914143 ·Status: UNKNOWN ·Phase: NA
-
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
NCT02530125 ·Status: TERMINATED ·Phase: PHASE2
-
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00009776 ·Status: UNKNOWN ·Phase: PHASE1
-
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
NCT01419795 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
NCT04922567 ·Status: RECRUITING ·Phase: PHASE2
-
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
NCT00911183 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
NCT00290667 ·Status: COMPLETED ·Phase: PHASE2
-
The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma
NCT02449278 ·Status: RECRUITING ·Phase: PHASE3
-
IMPACT Non Hodgkins Lymphoma (NHL) Study
NCT00903812 ·Status: COMPLETED